CD33 and acute myeloid leukemia: A recent phase I clinical trial using CD33-targeted CAR-NK-92 cells for the patients with recurrent refractory AML has shown no serious side effects, indicating that CAR-NK cells may be a safer alternative to CAR-T cells [146].